News Briefing channel feed

Life sci­ences fund rais­es €118M for its next round of bets; Gilead scraps Alpine al­liance

6 years ago

San­thera en­ters li­cense agree­ment with Chiesi Group; Tonix's co­caine in­tox­i­ca­tion drug, Io­vance's cer­vi­cal can­cer treat­ment win FDA's break­through sta­tus

6 years ago

Ar­ray shares surge as PhI­II sets the stage for FDA fil­ing; FDA gives Avadel pri­or­i­ty re­view

6 years ago

Top As­traZeneca I/O ex­ec jumps to Seat­tle Ge­net­ics as first CCO; Wood­ford fund down­grad­ed as woes mount

6 years ago

Take­da shares pos­i­tive Phase II­Ib da­ta; NIA grant for Phase II study on new oral Alzheimer's treat­ment

6 years ago

Take­da re­ceives ad­di­tion­al FDA ap­proval for GI drug; Can­cer Re­search UK to test gem­c­itabine for ad­vanced pan­cre­at­ic can­cer

6 years ago

Ab­b­Vie/Roche's Ven­clex­ta wins fourth ap­proval; WuXi, fel­low CRO Al­ta­sciences ink deal

6 years ago

Iso­Plex­is bags $25M to stoke T cell ther­a­py buzz; Col­lab­o­ra­tion be­tween X4 and LLS; New CMO at Pre­ci­sion Bio­sciences

6 years ago

Take­da fore­casts $1.7B loss af­ter Shire in­te­gra­tion; Flag­ship's pre­clin­i­cal biotech Ax­cel­la clos­es IPO with $71M+ haul

6 years ago

Bi­cy­cle sets terms for $65M IPO; Lil­ly's Cyra­mza wins fifth can­cer ap­proval

6 years ago

Lam­bast­ed by AIDS ac­tivists about Tru­va­da pric­ing, Gilead of­fers CDC drug sup­ply deal; Fi­bro­Gen MACE mis­com­mu­ni­ca­tion leaves in­vestors dis­ori­ent­ed

7 years ago

Gilead says on­ly Te­va can mar­ket Tru­va­da gener­ic; Den­ver nar­row­ly votes to de­crim­i­nal­ize "mag­ic mush­rooms"

7 years ago

BioN­Tech nabs PhI an­ti­body and a new US base out of bank­rupt­cy; Pfiz­er wins con­di­tion­al drug OK

7 years ago

Con­fo Ther­a­peu­tics rais­es €30 mil­lion; Waylivra re­ceives ap­proval from EU; end­point met for Mer­ck­'s Bel­som­ra in PhI­II tri­al

7 years ago

Es­pe­ri­on shares surge as FDA waves off pan­el re­view; Adap­ti­m­mune buoyed by a pos­i­tive da­ta snap­shot

7 years ago

FDA ex­pands ap­proval of Agios' Tib­so­vo; As­traZeneca's long-act­ing di­a­betes drug se­cures US nod

7 years ago

Cel­gene part­ners on Phase 0 can­cer drug stud­ies; FDA lifts clin­i­cal hold on Xen­cor's bis­pe­cif­ic

7 years ago

Ab­b­Vie nabs pe­di­atric OK for hep C drug Mavyret; Glen­mark launch­es cheap­er SGLT2 in­hibitor in In­dia

7 years ago

As­traZeneca teams with Benev­o­len­tAI on dis­cov­ery, re­search; Cam­bridge spin­out rais­es seed cash for pro­tein degra­da­tion work

7 years ago

Por­to­la gets EU clear­ance to mar­ket An­dexxa un­der new name; Four biotechs set terms for Nas­daq de­but

7 years ago

Cel­gene sub­mits EU mar­ket­ing pitch for lus­pa­ter­cept; Bausch Health wins FDA ap­proval for top­i­cal pso­ri­a­sis treat­ment

7 years ago

Af­ter Bio­gen ex­it, Mit­subishi Tan­abe Phar­ma links up with Sal­ix to de­vel­op amise­limod; Two drug de­vel­op­ers set up an­tibi­ot­ic col­lab­o­ra­tion

7 years ago

GSK plans $100M makeover of US man­u­fac­tur­ing site; La Jol­la Phar­ma gets a 'break­through' with late-stage drug

7 years ago

Re­gen­eron's Schleifer: Amer­i­can pub­lic com­pa­nies should fund 'in­fra­struc­ture bank'; Sher­lock clos­es $49M round for CRISPR di­ag­nos­tic work

7 years ago
First page Previous page 49505152535455 Next page Last page
A service from the Financial Times